Edition:
United States

Protalix Biotherapeutics Inc (PLX.A)

PLX.A on American Stock Exchange

0.30USD
9 Dec 2016
Change (% chg)

$0.00 (+0.98%)
Prev Close
$0.30
Open
$0.30
Day's High
$0.31
Day's Low
$0.29
Volume
119,067
Avg. Vol
63,521
52-wk High
$1.05
52-wk Low
$0.28

PLX.A

Chart for PLX.A

About

Protalix BioTherapeutics, Inc. is a biopharmaceutical company. The Company is focused on the development and commercialization of recombinant therapeutic proteins based on its ProCellEx protein expression system (ProCellEx). The Company has developed taliglucerase alfa (marketed under the name Uplyso in Brazil and certain other... (more)

Overall

Beta: 0.63
Market Cap(Mil.): ₪114.70
Shares Outstanding(Mil.): 99.93
Dividend: --
Yield (%): --

Financials

  PLX.A Industry Sector
P/E (TTM): -- 41.98 30.40
EPS (TTM): -1.35 -- --
ROI: -72.58 -0.36 15.24
ROE: -- -0.94 16.58

BRIEF-Alfataliglicerase approved for pediatric indications in Brazil for the treatment of gaucher disease in children four years and older

* Alfataliglicerase approved for pediatric indications in brazil for the treatment of gaucher disease in children four years and older

Nov 22 2016

BRIEF-Protalix Biotherapeutics reports Q3 loss per share of $0.07

* Protalix Biotherapeutics - cash and cash equivalents as of September 30, 2016 were $51.3 million, which provides company with capital into 2018

Nov 09 2016

BRIEF-Protalix Biotherapeutics doses first patient in global Phase III clinical trial of PRX-102

* Protalix Biotherapeutics doses first patient in global phase iii clinical trial of PRX-102 for the treatment of fabry disease Source text for Eikon: Further company coverage:

Oct 25 2016

BRIEF-Protalix Biotherapeutics updates on fabry disease trial

* Protalix biotherapeutics announces additional positive data from its phase i/ii clinical trial for PRX-102 for the treatment of fabry disease

Aug 10 2016

BRIEF-Protalix biotherapeutics reports Q2 loss per share $0.11

* Protalix Biotherapeutics reports second quarter 2016 financial results

Aug 08 2016

Earnings vs. Estimates